Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children with Leukemia

Launched by NATIONAL INSTITUTE OF PEDIATRICS, MEXICO · Aug 14, 2024

Keywords

ClinConnect Summary

Background Acute lymphoblastic leukemia (ALL) is a malignant disease characterized by the uncontrolled proliferation of immature lymphoid cells. It is the most common neoplasm in children, representing up to 53.1% of all oncologic processes in Mexico \[1-6\]. Fortunately, with the current chemotherapeutic treatments, disease remission is achieved in 98% of cases; however, the chemotherapeutic treatments have side effects that can lead to gastrointestinal toxicity (7.7 to 32.5%), which is associated with up to 50% mortality.

Among the most common gastrointestinal manifestations resulting fr...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients older than 6 years and younger than 17 years with a recent diagnosis of acute lymphoblastic leukemia, confirmed by bone marrow aspirate and interpreted by a pediatric oncologist.
• • Participants of both sexes
• • Participants receiving treatment at the Oncology Service of the Instituto Nacional de Pediatría.
• • Receiving chemotherapy according to national health protocols in the consolidation phase.
• • Informed consent
• • Informed assent for those older than 8 years.
• Exclusion Criteria:
• • Allergy to probiotics.
• • Consumption of another probiotic
• • Enteropathies affecting intestinal absorption (e.g., malabsorption syndrome, short bowel syndrome, intestinal malrotation, chronic nonspecific ulcerative colitis, Crohn's disease).
• • Chronic diarrhea (\>15 days of duration)
• • Presence of mucosal lesions
• • Impossibility of enteral feeding
• • Renal insufficiency
• • Peritoneal dialysis
• • Water and electrolyte disorders
• • Surgical intestinal bypass (e.g., colostomy, ileostomy)
• • Congenital metabolic disorders
• • Septicemia
• • Body temperature \> 38° C
• • Received broad-spectrum antibiotics (piperacillin/tazobactam, fourth generation cephalosporins, aminoglycosides, carbapenem and/or metronidazole) within the past 30 days.